Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai gives lymphoma program back to Epizyme

This article was originally published in Scrip

Executive Summary

Eisai has given all development and commercialization rights of its EZH2 program, except for in the Japanese market, back to originator company Epizyme. The program includes lymphoma therapy EPZ-6438, a first-in-class inhibitor of EZH2, which is currently being evaluated in Phase I/II clinical studies. Under the new agreement, Epizyme will make a $40m upfront payment to Eisai, with a total of up to $20m in potential clinical milestone payments and up to $50m in potential regulatory milestone payments. Epizyme will pay Eisai a royalty at a percentage in the mid-teens on sales of EPZ-6438 outside of Japan, and Eisai will pay Epizyme a royalty at a percentage in the mid-teens on sales in Japan. Eisai will have a limited right of first negotiation for Asia rights if Epizyme decides to license Asia rights to a third party. Following completion of the transition of EPZ-6438 from Eisai to Epizyme, the Massachusetts-based biopharma plans to conduct a five-arm Phase II study in approximately 150 patients with non-Hodgkin's lymphoma.

You may also be interested in...

Femtech Presents Enticing Market Opportunity

A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.

Execs On The Move, Sep 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Snapshot: September Highlights

A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts